Drogsan and Rockwell Enter into License Agreement Concerning 65k Hemodialysis Patients in Turkey

Drogsan, one of Turkey’s leading pharmaceutical companies, will introduce Rockwell’s innovative iron deficiency anemia treatment to the Turkish market.

Drogsan Pharmaceuticals, one of Turkey’s leading pharmaceutical companies, collaborated with US-based biopharmaceutical company Rockwell Medical to launch their new FDA-approved product in Turkey.

Having introduced Turkey’s first biosimilar drug in 2014, Drogsan, a nephrology expert, joined forces with Rockwell, which is dedicated to transforming iron deficiency treatment and anemia management. With this collaboration, Drogsan will be able to commercialize the innovative drug developed by Rockwell to treat iron deficiency anemia in hemodialysis patients in Turkey and surrounding region.

Mustafa Karpuzcu, Chairman and CEO of Drogsan Pharmaceuticals, said: “We welcome this opportunity to collaborate with Rockwell Medical and bring this innovative treatment to hemodialysis patients in Turkey. There are approximately 65.000 hemodialysis patients in Turkey and the number of these patients is expected to continue to increase every day. We believe this partnership is vital to addressing the need for an effective, safe and innovative treatment for patients with iron deficiency anemia.”

As we continue to drive opportunities to bring Triferic to patients around the world, this agreement represents important progress to address the needs of iron deficient patients in Turkey,” said Russell Ellison, M.D., President and CEO of Rockwell Medical: “Drogsan has a solid history in this field with its 45 years of pharmaceutical experience, with a robust infrastructure, successful product launches, and a highly experienced nephrology team. For this reason, we look forward to working closely with Drogsan, which is our partner of choice, to bring our innovative product to patients in need.”